| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -6.2 | -16.4 |
| EPS (diluted, $ a share) | $-0.09 | $-0.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BMEA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biomea Fusion, Inc.: key numbers
- Share price
- $0.4880Close, Nov 17
- Market cap
- $35.5M
- Shares outstanding
- 72.68MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biomea Fusion, Inc.
All →Biomea Fusion Financial Results
Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.
- Term
- Q3 2026
“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”
Mick Hitchcock, Ph.D., Interim Chief Executive Officer
“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”
Mick Hitchcock, Ph.D., Interim Chief Executive Officer
Biomea Fusion Clinical Trial Data
Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.
Biomea Fusion Clinical Trial Data
Biomea Fusion updated the anticipated timing for topline results from its Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The company now expects to release the data in October 2026.